Here are the 424B prospectus supplements from Century Therapeutics, Inc. (IPSC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IPSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPSC filings page.
IPSC registers the resale of up to 176,086,947 shares of common stock for resale or other disposition by the selling stockholders named in the prospectus supplement.
This supplement substitutes SILV Fund, Ltd. for Point72 Associates, LLC in the selling stockholders table and updates that holder's row to reflect a prior ownership of 7,057,359 shares and a maximum of 3,260,869 shares to be sold under the prospectus. Shares outstanding were 180,102,343 as of March 31, 2026.
Century Therapeutics is registering up to $150,000,000 of common stock for sale in an at-the-market offering through TD Cowen pursuant to an existing sales agreement.
The prospectus supplement states 87,519,096 shares outstanding as of December 31, 2025, after giving effect to the January 2026 private placement. Sales will be made from time to time at market prices, TD Cowen will receive a 3.0% commission, and proceeds will be received by the issuer.